ISCT 2020 | Barriers to CAR-T for glioblastoma

Khaled Sanbar, MD, PhD, Johns Hopkins Hospital, Baltimore, MD, explores challenges in implementing CAR T-cell therapies for glioblastoma routine treatment, including administration, antigen heterogeneity of tumors, and persistence of the CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).